DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,469,065 B1 Garvey Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,469,065 B1 Garvey Et Al USOO6469.065B1 (12) United States Patent (10) Patent No.: US 6,469,065 B1 Garvey et al. (45) Date of Patent: Oct. 22, 2002 (54) NITROSATED AND NITROSYLATED 5,612,314 A 3/1997 Stamler et al. C-ADRENERGIC RECEPTOR ANTAGONIST, 5,635,204 A 6/1997 Gevirtz et al. .............. 424/449 COMPOSITIONS AND METHODS OF USE 5,646,181 A 7/1997 Fung et al. 5,648,393 A 7/1997 Stamler et al. 5,698,589 A 12/1997 Allen (75) Inventors: David S. Garvey, Dover; Joseph D. 5,731,339 A 3/1998 Lowrey Schroeder, Dedham, both of MA (US); 5,767,160 A 6/1998 Kaesemeyer Inigo Saenez de Tejada, Madrid (ES); 5,773,457 A 6/1998 Nahoum Ricky D. Gaston, Malden, MA (US); 5,789.442 A 8/1998 Garfield et al. Tatiana E. Shelekhin, Acton, MA 5,877,216 A 3/1999 Place et al. (US); Tiansheng Wang, Concord, MA (US) FOREIGN PATENT DOCUMENTS EP O346297 12/1989 (73) Assignee: NitroMed, Inc., Bedford, MA (US) EP O357581 3/1990 EP O432199 6/1991 (*) Notice: Subject to any disclaimer, the term of this FR 2547SO1 12/1984 patent is extended or adjusted under 35 JP 8O26962 1/1998 U.S.C. 154(b) by 0 days. WO 97/27749 * 8/1997 WO 97.27749 8/1997 WO 97.42.946 11/1997 (21) Appl. No.: 09/387,724 WO 9852569 11/1998 Filed: Sep. 1, 1999 WO 99.01132 1/1999 (22) WO 9907353 2/1999 WO 99.07695 2/1999 Related U.S. Application Data WO 992S345 5/1999 (63) Continuation-in-part of application No. 09/145,143, filed on WO 9930697 6/1999 Sep. 1, 1998, now Pat. No. 6.294,517, which is a continu ation-in-part of application No. 08/714,313, filed on Sep. 18, OTHER PUBLICATIONS 1996, now Pat. No. 5,994,294, which is a continuation-in part of application No. 08/595,732, filed on Feb. 2, 1996, Buvat et al, The Journal of Urology, 141 (6): 1364–1367 now Pat. No. 5,932,538. (1989). (51) Int. Cl........................ A61K31/135; A61K 31/21 Costa et al, The Journal of Urology, 149:301-305 (1993). (52) U.S. Cl. ....................... 514/546; 514/506; 514/617; Burnett, The Journal of Urology, 157:320-324 (1997). 514/651; 536/103; 540/1; 540/147; 540/155; (List continued on next page.) 548/500; 564/45 (58) Field of Search ................................. 514/546, 506, Primary Examiner Bennett Celsa 514/617, 651; 536/103; 540/1; 560/147, (74) Attorney, Agent, or Firm-Hale and Dorr LLP 155; 548/500; 564/45 (57) ABSTRACT (56) References Cited The present invention describes novel nitrosated and/or U.S. PATENT DOCUMENTS nitrosylated C.-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or 4,127,118 A 11/1978 Latorre nitrosylated C.-adrenergic receptor antagonist, and, 4,590,202 A 5/1986 Remy ......................... 514/392 4,801,587 A 1/1989 Voss et al. optionally, one or more compounds that donate, transfer or 4.885,173 A 12/1989 Stanley et al. release nitric oxide, elevate endogenous levels of 5,059,603 A 10/1991 Rubin endothelium-derived relaxing factor, Stimulate endogenous 5,145,852 A 9/1992 Virag Synthesis of nitric oxide or are a Substrate for nitric oxide 5,190,967 A 3/1993 Riley Synthase, and/or one or more vasoactive agents. The present 5,236,904 A 8/1993 Gerstenberg et al. invention also provides novel compositions containing at 5,256,652 A 10/1993 El-Rashidy least one O-adrenergic receptor antagonist, and one or more 5,281,607 A 1/1994 Stone et al. ................ 514/280 compounds that donate, transfer or release nitric oxide, 5,380,758 A 1/1995 Stamler et al. elevate endogenous levels of endothelium-derived relaxing 5,399,581 A 3/1995 Laragh 5,403,847. A 4/1995 Gluchowski et al. ....... 514/318 factor, Stimulate endogenous Synthesis of nitric oxide or is a 5.439,938 A 8/1995 Snyder et al. Substrate for nitric oxide Synthase and/or one or more 5,447.912 A 9/1995 Gerstenberg et al. vasoactive agents. The present invention also provides 5,451,609 A 9/1995 Bellamy et al. ............ 514/651 methods for treating or preventing Sexual dysfunctions in 5,474,535 A 12/1995 Place et al. males and females, for enhancing Sexual responses in males 5.492.911 A 2/1996 Stief and females, and for treating or preventing benign prostatic 5,498.623 A 3/1996 Karjalainen et al. ........ 514/396 hyperplasia, hypertension, congestive heart failure, variant 5,543,430 A 8/1996 Kaesemeyer (Print Zmetal) angina, glaucoma, neurodegenerative 5,565,466 A 10/1996 Gioco et al. disorders, vasospastic diseases, cognitive disorders, urge 5,567,706 A 10/1996 Gavras 5,574,068 A 11/1996 Stamler et al. incontinence, or overactive bladder, and for reversing the 5,578,611 A 11/1996 Gluchowski et al. ....... 514/318 State of anesthesia. 5,583,144. A 12/1996 Kral 5,593.876 A 1/1997 Stamler et al. 19 Claims, 11 Drawing Sheets US 6,469,065 B1 Page 2 OTHER PUBLICATIONS Physicians Desk Reference, 48th Edition, pp. 1146-1147 Buvat et al, The Journal of Urology, 159:116-119 (Jan. (1994). 1998). Zorgniotti et al, Int. J. Impotence Res., 6:33-36 (1994). Saenz de Tejada et al, The Journal of Pharmacology and Trigo-Rocha et al., Neuroulogy and Urodynamics, 13:71-80 Experimental Therapeutics, 290(1):121-128 (1999). (1994). Mathers et al., European Urology, 35(suppl 2):67 (abstract Sonda et al., Journal of Sex & Marital Therapy, 16(1):15-21 266) (1999). (1990). RBI/Sigma Catalog, p. 354 (1999). Marquer et al., Fundam Clin Pharmacol, 12:377–387 (1998). The Merck Index, 12th Edition, pp. 132, 1727 and 1728 (1996). * cited by examiner U.S. Patent Oct. 22, 2002 Sheet 1 of 11 US 6,469,065 B1 Figure I 12O — -rurummittanowawm-w 1 OO 8O 60 40 O -- Example 1 Example 1 Yohimbine Yohimbine (500 ug) (500 ug) (150 ug) (500 ug) -- Yohimbine (150 ug) U.S. Patent Oct. 22, 2002 Sheet 2 of 11 US 6,469,065 B1 Figure 2 Yohimbine (150 lug) Yohimbine (500 ug) Example (500 Lug) Example 1 + Yohimbine (500 ug) (150 ug) O 10 20 30 40 5O (Duration (min) U.S. Patent Oct. 22, 2002 Sheet 3 of 11 US 6,469,065 B1 Figure 3 4O -area 12O OO 68 OO 4. O O -T- Example 2 Example 2 Yohimbine Yohimbine Yohimbine (500 ug) (1 mg) (150 lug) (500 ug) (1 mg) U.S. Patent Oct. 22, 2002 Sheet 4 of 11 US 6,469,065 B1 Figure 4 Yohimbine (1 mg) Yohimbine (500 g) Yohimbine (150 ug) Example 2 (1 mg) (500 ug) - 15 20 25 30 35 Duration (min) U.S. Patent Oct. 22, 2002 Sheet 5 of 11 US 6,469,065 B1 L. Ot D C?) C T2 E LILLIrish I III-III a LL EXAMPLE 2 H.-- (500pg) MINUTE FIG.5A O O S. EEE H. O. O. O. 2 l PAP/PHENT/PGE s -- MINUTE FIG.5B U.S. Patent Oct. 22, 2002 Sheet 6 of 11 US 6,469,065 B1 Figure 6 1 OO racareer 468OOO 2 O Example 6 Moxisylyte (1 mg) (1 mg) U.S. Patent Oct. 22, 2002 Sheet 7 of 11 US 6,469,065 B1 Figure 7 Moxisylyte (1 mg) Moxisylyte (2 mg) Example 6 (1 mg) Example 6 (2 mg) O 1o 20 30 40 Duration (min) U.S. Patent Oct. 22, 2002 Sheet 8 of 11 US 6,469,065 B1 Figure 8 12 O --- GS 8 1 OO 8. I o -------a -- C) 8 O CC s is 60 On C 4 O 2 O O --- O.2 mg 0.4 mg 0.8 mg 1.6mg Dose (Example 9) U.S. Patent Oct. 22, 2002 Sheet 9 of 11 US 6,469,065 B1 Figure 9 1 OO --- 9 O ara 8 O 85 7 O C E 6 O Z 5 O O CC 4 O D 3 O O 2O | 1 O O --- 0.2 mg 0.4 mg O.8 mg 1.6mg Dose (Example 9) U.S. Patent Oct. 22, 2002 Sheet 10 of 11 US 6,469,065 B1 Figure 10 1 OO --- 9 O 80 7 O 6 O 5 O 4 O 3 C. -T- 20 : 1 O O -- 0.64 mg 1.07 mg 2.13 mg 4.26 mg Dose (Example 10) U.S. Patent Oct. 22, 2002 Sheet 11 of 11 US 6,469,065 B1 Figure 11 1 4 O -------- 12 O 16 SB 100 CS . 5 80 s 6 O H C 4 O ?h 2O O --- 0.64 mg 1.07 mg 2.13 mg 4.26 mg Dose (Example 10) US 6,469,065 B1 1 2 NITROSATED AND NITROSYLATED Sexual response is the erectile response. The erectile C-ADRENERGIC RECEPTOR ANTAGONIST, response in both males and females is the result of engorge COMPOSITIONS AND METHODS OF USE ment of the erectile tissues of the genitalia with blood which is caused by the relaxation of Smooth muscles in the arteries RELATED APPLICATIONS Serving the genitalia. In both pre-menopausal and menopausal females, Sexual This application is a continuation-in-part of U.S. appli dysfunction can include, for example, Sexual pain disorders, cation Ser. No. 09/145,143, filed Sep. 1, 1998, now U.S.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Adrenoceptor Subtype 1Ian Marshall, Richard P
    Brifish Journal of Pharmacology (I995) 115, 781 - 786 1995 Stockton Press All rights reserved 0007-1188/95 $12.00 X Noradrenaline contractions of human prostate mediated by aClA- (cxlc) adrenoceptor subtype 1Ian Marshall, Richard P. Burt & *Christopher R. Chapple Department of Pharmacology, University College London, Gower Street, London WC1E 6BT and *Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield SlO 2JF 1 The subtype of a1-adrenoceptor mediating contractions of human prostate to noradrenaline was characterized by use of a range of competitive and non-competitive antagonists. 2 Contractions of the prostate to either noradrenaline (pD2 5.5), phenylephrine (pD2 5.1) or methoxamine (pD2 4.4) were unaltered by the presence of neuronal and extraneuronal uptake blockers. Noradrenaline was about 3 and 10 times more potent than phenylephrine and methoxamine respectively. Phenylephrine and methoxamine were partial agonists. 3 Pretreatment with the alkylating agent, chlorethylclonidine (10-4 M) shifted the noradrenaline concentration-contraction curve about 3 fold to the right and depressed the maximum response by 31%. This shift is 100 fold less than that previously shown to be produced by chlorethylclonidine under the same conditions on OlB-adrenoceptor-mediated contractions. 4 Cumulative concentration-contraction curves for noradrenaline were competitively antagonized by WB 4101 (pA2 9.0), 5-methyl-urapidil (pA2 8.6), phentolamine (pA2 7.6), benoxathian (pA2 8.5), spiperone (pA2 7.3), indoramin (pA2 8.2) and BMY 7378 (pA2 6.6). These values correlated best with published pKi values for their displacement of [3H]-prazosin binding on membranes expressing cloned oczc-adrenoceptors and poorly with values from cloned lb- and cld-adrenoceptors.
    [Show full text]
  • Adrenoreceptors F
    Stimulation of in vitro ovulation and contraction of brook trout (Salvelinus fontinalis) follicles by adrenaline through \g=a\-adrenoreceptors F. W. Goetz and J. A. Bradley University of Notre Dame, Department of Biological Sciences, Notre Dame, ID 46556, USA The effects of adrenaline and adrenoreceptor antagonists on ovulation and follicle wall contraction were investigated in brook trout (Salvelinus fontinalis) follicles using in vitro incubation systems. Adrenaline significantly stimulated a dose-dependent increase in ovu- lation and follicle contraction at concentrations between 1.0 and 100 \g=m\moll \m=-\1 The ovulatory and contractile effects of 10 \g=m\mol adrenaline l \m=-\1 could be blocked by the \g=a\1-adrenoreceptorantagonists WB-4101 and benoxathian, and by the \g=a\2-antagonist yohim- bine. WB-4101 was the most potent blocker, significantly inhibiting ovulation and con- traction at 1.0 \g=m\mol l\m=-\1. In contrast, the \g=b\-antagonistpropranolol (100\p=n-\0.001\g=m\moll\m=-\1) was totally ineffective in blocking adrenaline-induced ovulation and follicle contraction. The results indicate that there is a strong correlation between the effects of adrenaline on ovulation and contraction. In addition, the antagonist studies indicate that adrena- line stimulates ovulation and follicle contraction of brook trout follicles through \g=a\-adrenoreceptors. Introduction follicles in smaller mammals has not been reported. In addition, while the perfused ovary system may be free of extraovarian Evidence that catecholamines play a direct role in the control of influences, it is still possible that the effects of certain agents in vertebrate ovulation comes from a variety of investigations this system act through vascular changes in the follicle rather (Goetz et al, 1991).
    [Show full text]
  • Analysis 'David Sugden, Naveed Anwar & *David C
    Bridsh Joumal of Phamacology (1996) 118, 1246 1252 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 0 Rat pineal acx-adrenoceptor subtypes: studies using radioligand binding and reverse transcription-polymerase chain reaction analysis 'David Sugden, Naveed Anwar & *David C. Klein Physiology Group, Biomedical Sciences Division, King's College London, Campden Hill Road, London W8 7AH and *Section on Neuroendocrinology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, U.S.A. 1 The pharmacological characteristics of a,-adrenoceptor binding sites in rat pineal gland membranes, detected by use of a selective a,-adrenoceptor antagonist ([I25I]-iodo-2-[#-(4-hydroxyphenyl) ethylami- nomethyl]tetralone, [125I]-HEAT), were investigated with the alkylating agent, chloroethylclonidine (CEC), and in competition experiments with a number of adrenoceptor agonists and antagonists. 2 Chloroethylclonidine (CEC) treatment (10 gM, 10 min) of rat pineal membranes inactivated -70% of specific ['251]-HEAT binding sites. Higher concentrations of CEC (up to 100 gM) or longer treatment periods (upto 40 min) were no more effective. 3 Adrenoceptor agonists and antagonists competitively inhibited [1251]-HEAT binding with Hill coefficients close to unity indicating a single a1-adrenoceptor subtype is present. The affinity (Ki) of subtype selective agonists (oxymetazoline, SDZ NVI-085) and antagonists (5-methylurapidil, WB4101, benoxathian, phentolamine) was consistent with binding to an xB-adrenoceptor subtype. 4 The (-)- and (+)-enantiomers of niguldipine had an equal and low affinity for a,-adrenoceptor binding sites both in untreated (log K -6.66 and -6.90 respectively) and CEC-treated membranes in which -70% of sites had been inactivated (log Ki-6.41 and -6.86 respectively).
    [Show full text]
  • In Rat Cerebral Cortex and Vas Deferens 'B.A
    Br. J. Pharmacol. (1994), 111, 1003-1008 'PI Macmillan Press Ltd, 1994 Pharmacological properties of the cloned XlA/D-adrenoceptor subtype are consistent with the xlA-adrenoceptor characterized in rat cerebral cortex and vas deferens 'B.A. Kenny, A.M. Naylor, P.M. Greengrass, M.J. Russell, *S.J. Friend, A.M. Read & M.G. Wyllie Departments of Discovery Biology and *Molecular Genetics, Pfizer Central Research, Sandwich, Kent CT13 9NJ 1 The pharmacological characteristics of cloned mammalian &1IA/D-, aIB- and x1c-adrenoceptor subtypes expressed in rat 1 fibroblasts were determined in comparison to the binding and functional properties of these subtypes in rat tissues. 2 Analysis of [3H]-prazosin binding to membrane homogenates from rat 1 fibroblast cells expressing each of the al-subtypes indicated high affinity binding to a single population of binding sites. Binding affinities were similar for 01A/D-, OeB- and mlc-subtypes (Kds: 0.13, 0.10 and 0.15 nM respectively) although a higher density of aXB- and ocic-receptors (Bwx 4068 and 10,323 fmol mg1l protein respectively) were expressed in comparison to O1A/D (838 fmol mg'). 3 Displacement of [3H]-prazosin from membranes expressing cloned al-adrenoceptor subtypes revealed that 5-methyl-urapidil, WB 4101, benoxathian and phentolamine displayed high affinity and selectivity for C1A/D- over (1B-subtypes. These compounds also had high affinity and selectivity for qlc- over ajB-subtypes. 5-Methyl-urapidil showed selectivity for a&c (Ki 0.60 + 0.16 nM) over both MIA/D (Ki, 9.8 ± 2.8 nM) and aCB (K, 57.2 ± 12 nM) subtypes.
    [Show full text]
  • (C) Hit Agreement Between Seeding Densities
    (a) Morphological space (b) Identification of hits (c) Hit agreement between 1500 cells per well 1500 cells per well seeding densities DMSO 8 1.00 Pentamidine 1.00 Wiskostatin Hydroxychloroquine Imatinib 0.75 0.75 4 Gefitinib Compound DMSO Pentamidine 0.50 0.50 0 Vinblastine UMAP2 Wiskostatin Vinblastine 0.25 0.25 Vinblastine −4 Plate at 1500 cells/well Robust Hellinger Distance Wiskostatin Pentamidine 0.00 DMSO 0.00 −4 0 4 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 UMAP1 FDR−corrected p−value Plate at 750 cells/well Supp. Figure 1: BioProfiling.jl profiles of plates seeded at 750 and 1500 cells per well curated with are similar. (a) UMAP embedding preserving the cosine distance between the mor-phological profiles aggregated per field of view in the plate seeded with 1500 cells per well. Two out of four dimensions are represented. (b) Robust Hellinger distance and Ro-bust Morphological Perturbation Value (FDR-corrected p-value) of each compound in the plate seeded with 1500 cells per well compared to DMSO. Vertical dotted line indicates an FDR threshold of 0.1 and all compounds on its left are defined as morphological hits. (c) FDR-corrected p-value of the significance of morphological changes induced by each compound in both plates. Dotted lines indicate an FDR threshold of 0.1. CompoundName MOA Targets RMPV750 RMPV1500 (+)-Butaclamol hydrochloride 0.2479179 0 (+)-Cyclazocine 0.0288018 0.0012478 ["ABCC1", "ABCC2", "FPR1", (+/-)-Sulfinpyrazone ["Uricosuric blocker"] "SLC22A12"] 0.0019172 0.015413 (-)-JQ1 0.0003682 0 (-)-Perillic
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao Et Al
    USOO8637524B2 (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao et al. (45) Date of Patent: Jan. 28, 2014 (54) PYRIMIDINONE INHIBITORS OF Tonn, Biological Mass Spectrometry vol. 22 Issue 11, pp. 633-642 LIPOPROTEIN-ASSOCATED (1993).* PHOSPHOLPASE A2 Hist Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277 Wolen, Journal of Clinical Pharmacology 1986; 26: 419-424.* (75) Inventors: Tadimeti Rao, San Diego, CA (US); Browne, Journal of Clinical Pharmacology 1998; 38: 213-220.* Chengzhi Zhang, San Diego, CA (US) Baillie, Pharmacology Rev. 1981: 33:81-132.* Gouyette, Biomedical and Environmental Mass Spectrometry, vol. (73) Assignee: Auspex Pharmaceuticals, Inc, La Jolla, 15, 243-247 (1988).* CA (US) Cherrah, Biomedical and Environmental Mass Spectrometry vol. 14 Issue 11, pp. 653-657 (1987).* Pieniaszek, J. Clin Pharmacol. 1999; 39: 817-825.* (*) Notice: Subject to any disclaimer, the term of this Honma et al., Drug Metab Dispos 15 (4): 551 (1987).* patent is extended or adjusted under 35 Kushner, D. Jet al., Pharmacological uses and perspectives of heavy U.S.C. 154(b) by 58 days. water and deuterated compounds, Can. J. Physiol. Pharmacol. (1999), 77, 79-88. (21) Appl. No.: 12/840,725 Bauer et al., Influence of long-term infusions on lidocaine kinetics, Clin. Pharmacol. Ther. (1982), 31(4), 433-7. (22) Filed: Jul. 21, 2010 Borgstrom et al., Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect, J Pharm. Sci., (1988), 77(11) 952-4. (65) Prior Publication Data Browne et al., Chapter 2. Isotope Effect: Implications for pharma US 2011/0306552 A1 Dec.
    [Show full text]
  • Blockade of Alpha1 Adrenoreceptors in the Dorsal Raphe Nucleus
    Behavioural Brain Research 134 (2002) 387Á/392 www.elsevier.com/locate/bbr Research report Blockade of alpha1 adrenoreceptors in the dorsal raphe nucleus prevents enhanced conditioned fear and impaired escape performance following uncontrollable stressor exposure in rats Ruth E. Grahn a,*, S.E. Hammack a, M.J. Will b, K.A. O’Connor a, T. Deak c, P.D. Sparks a, L.R. Watkins a, S.F. Maier a a Department of Psychology, Campus Box 345, University of Colorado, Boulder, CO 80309, USA b Department of Psychology, WISPIC, 6001 Research Park Blvd, Rm 1026, Madison, WI 53719, USA c Department of Psychology, Terrence Deak, SUNY-Binghamton, Binghampton, NY 13902-6000, USA Received 16 August 2001; received in revised form 28 February 2002; accepted 28 February 2002 Abstract Previous research has shown that the effect of exposure to uncontrollable stressors on conditioned fear responding and escape behavior in rats is dependent on serotonergic neural activity in the dorsal raphe nucleus (DRN). The role that norepinephrine released in the DRN plays in producing the behavioral consequences of exposure to inescapable tail shock in rats was investigated in the present study. The selective alpha1 adrenoreceptor antagonist benoxathian was injected into the DRN before exposure to inescapable tail shock or before behavioral testing conducted 24 h later. Benoxathian prevented the impairment of escape responding produced by inescapable shock, but did not reverse this effect when given before testing. The enhancement of conditioned fear produced by prior inescapable shock was attenuated by benoxathian administered before inescapable shock or before behavioral testing. These results support the view that noradrenergic input to the DRN is necessary to produce the behavioral effects of inescapable tail shock.
    [Show full text]
  • FROM DIAGNOSIS to THERAPY by Reety Arora Bachelors in Engineerin
    MERKEL CELL POLYOMAVIRUS POSITIVE MERKEL CELL CARCINOMA – FROM DIAGNOSIS TO THERAPY by Reety Arora Bachelors in Engineering, Panjab University, 2007 Submitted to the Graduate Faculty of University of Pittsburgh School of Medicine, Program in Integrative Molecular Biology, in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2012 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Reety Arora It was defended on May 4, 2012 and approved by Jeffrey L.Brodsky, Ph.D., Professor, Department of Biological Sciences James M. Pipas, Ph.D., Professor, Department of Biological Sciences Saleem A. Khan, Ph. D., Professor, Department of Microbiology and Molecular Genetics Thomas E. Smithgall, Ph. D., Professor, Department of Microbiology and Molecular Genetics Dissertation Advisor: Yuan Chang, MD, Professor, Department of Pathology ii Copyright © by Reety Arora 2012 iii MERKEL CELL POLYOMAVIRUS POSITIVE MERKEL CELL CARCINOMA - FROM DIAGNOSIS TO THERAPY Reety Arora University of Pittsburgh, 2012 Merkel cell polyomavirus (MCV) is one of the newer members of the polyomavirus family, recently discovered as clonally integrated into the genomes of a subset of Merkel cell carcinoma (MCC). MCV is the first polyomavirus that is widely accepted to cause a human cancer and its identification has resulted in a paradigm shift in the understanding of MCC biology. In the vast majority of the population, MCV is a harmless member of the normal human microbial flora, but can initiate an aggressive cancer if it integrates into the host genome and acquires a precise set of viral mutations that result in replication incompetence (in a susceptible host).
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfrlm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor, Ml 48106-1346 USA 313/761-4700 800.521-0600 Order Number 9120656 Characterization of ai-adrenergic receptor mediated DNA and protein syntheses in primary cultured rat hepatocytes Esbenshade, Timothy Allan, Ph.D.
    [Show full text]
  • Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Non-Lipid Benzofuran Ethanolamine Structures
    JPET Fast Forward. Published on May 14, 2020 as DOI: 10.1124/jpet.120.265454 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 265454 Title page Lysophosphatidic acid receptor agonism: discovery of potent non- lipid benzofuran ethanolamine structures Authors: Etienne Guillot, Jean-Christophe Le Bail, Pascal Paul, Valérie Fourgous, Pascale Briand, Michel Partiseti, Bruno Cornet, Philip Janiak, Christophe Philippo Downloaded from jpet.aspetjournals.org Principal affiliation: Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France at ASPET Journals on September 27, 2021 In detail affiliations EG, JCLB, PB, PJ: Diabetes and Cardiovascular Unit, Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France CP: Global Research Portfolio and Project Management, Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France PP, VF: Translational Science Unit, Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly- Mazarin, France BC: In-silico design, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France MP: Integrated Drug Discovery, Sanofi R&D, 13 quai Jules Guesde, 94400 Vitry-Sur-Seine, France 1 JPET Fast Forward. Published on May 14, 2020 as DOI: 10.1124/jpet.120.265454 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 265454 Running Title Page a) Running title: New potent non-lipid lysophosphatidic acid receptor agonists Downloaded from b) Corresponding author: Dr. Etienne Guillot, PhD jpet.aspetjournals.org Sanofi R&D, 1, avenue Pierre Brossolette, 91385 Chilly-Mazarin, France Tel: + 33.1.60.49.67.58-cell +33.6.07.25.90.86 at ASPET Journals on September 27, 2021 Email: [email protected] c) Number of text pages: 41 Number of tables: 2 (Supplemental: 4) Number of figures: 10 (Supplemental: 1) Number of references: 44 Number of words in abstract: 247 Number of words in introduction: 737 Number of words in discussion: 1488 2 JPET Fast Forward.
    [Show full text]
  • Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2020/05/14/jpet.120.265454.DC1 1521-0103/374/2/283–294$35.00 https://doi.org/10.1124/jpet.120.265454 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 374:283–294, August 2020 Copyright ª 2020 by The American Society for Pharmacology and Experimental Therapeutics Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures s Etienne Guillot, Jean-Christophe Le Bail, Pascal Paul, Valérie Fourgous, Pascale Briand, Michel Partiseti, Bruno Cornet, Philip Janiak, and Christophe Philippo Diabetes and Cardiovascular Unit, Sanofi R&D, Chilly-Mazarin, France (E.G., J.C.L.B., P.B., P.J.); Global Research Portfolio and Project Management, Sanofi R&D, Chilly-Mazarin, France (C.P.); Translational Science Unit, Sanofi R&D, Chilly-Mazarin, France (P.P., V.F.); In-silico design, Chilly-Mazarin, France (B.C.); and Integrated Drug Discovery, Sanofi R&D, Vitry-Sur-Seine, France (M.P.) Received January 30, 2020; accepted May 11, 2020 Downloaded from ABSTRACT Lysophosphatidic acid (LPA) is the natural ligand for two potent agonist, CpY, doubled intraurethral pressure in anesthetized phylogenetically distinct families of receptors (LPA1–3, LPA4–6) female rats at 3 mg/kg i.v. Alternatively, CpX was shown to inhibit whose pathways control a variety of physiologic and patho- human preadipocyte differentiation, a process totally reversed by physiological responses. Identifying the benefit of balanced KI16425. Together with original molecular docking data, these jpet.aspetjournals.org activation/repression of LPA receptors has always been a challenge findings clearly established these molecules as potent agonists of because of the high lability of LPA and the limited availability of LPA1–3 and consolidated the pivotal role of LPA1 in urethra/prostate selective and/or stable agonists.
    [Show full text]